M. Alejandra Tortorici

The paper shows repeated SARS-CoV-2 vaccine boosters elicit variant-specific memory B cells and neutralizing antibodies, suggesting immune imprinting can be overcome with updated vaccines.

This paper describes a miniprotein inhibitor that neutralizes multiple SARS-CoV-2 variants and protects mice against them when administered post-exposure.

This study designs miniproteins that inhibit MERS-CoV by targeting the spike protein, showing broad neutralization and protective efficacy in mice.

HKU5 merbecoviruses use bat Pipistrellus abramus ACE2 and several artiodactyl ACE2s through a cryo-EM-defined binding mode distinct from other ACE2-using coronaviruses, showing independent evolution of ACE2 usage.

The paper identifies two European bat MERS-related coronaviruses that use ACE2 as their receptor, revealing a distinct binding mode and host tropism determinants.

The paper isolates two human monoclonal antibodies that broadly neutralize PDCoV variants and identifies their mechanism of action.

This study identifies molecular mechanisms of FCoV-23 pathogenicity, including receptor usage and biotype switching, and identifies a cross-reactive antibody for therapeutic development.

This study determines the structure of HKU1 spike RBD bound to TMPRSS2, identifies host receptor usage determinants, and shows the role of antibodies and glycan shielding in neutralization.

This study shows that immune imprinting from prior Wuhan-Hu-1 spike exposure persists after XBB.1.5 vaccine booster, with neutralizing antibodies dominated by pre-existing memory B cells.